JOURNAL OF BUON, cilt.18, sa.4, ss.831-837, 2013 (SCI-Expanded)
Purpose: To evaluate the activity and toxicity of the combination of capecitabine and cisplatin (CapCisp) in anthracycline- and taxane-pretreated HER-2 negative metastatic breast carcinoma (MBC) female patients.